Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 10;8:15057. doi: 10.1038/s41598-018-32888-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Identification of proliferation- or differentiation-specific acetyltransferases. (A) Quantitative RT-PCR analysis of the indicated genes in the proliferation (blue bars) and muscle differentiation (red bars) stages (n = 3 each group). **p < 0.005. (B) Immunoblotting analysis of KAT2B and CBP in the proliferation (Pro) and differentiation (Diff) stages. Full-length blots are presented in Supplementary Fig. 6. (C) ChIP-qPCR analysis of KAT2B and β-catenin binding on the promoter regions of the indicated genes. ChIP with IgG at proliferation (Pro) stage (light blue), α-KAT2B antibody at proliferation stage (light green), α-β-catenin antibody at proliferation stage (red), IgG at myogenic differentiation (Diff) stage (light blue), α-KAT2B antibody at myogenic differentiation stage (light green), and), and α-β-catenin antibody at myogenic differentiation stage (red) (n = 3 each group). **p < 0.01, ***p < 0.001. (D) ChIP-qPCR analysis of CBP binding on the promoter regions of Fermt2. ChIP with IgG at proliferation (Pro) stage (light blue), α-CBP antibody at proliferation stage (light green), α-β-catenin antibody at proliferation stage (red), IgG at myogenic differentiation (Diff) stage (light blue), α-CBP antibody at myogenic differentiation stage (light green), and α-β-catenin antibody at myogenic differentiation stage (red) (n = 3 each group). **p < 0.01. (E) ChIP-qPCR analysis of H3K9Ac on the promoter regions of the indicated genes. ChIP with IgG at proliferation (Pro) stage (green), α-H3K9Ac antibody at proliferation stage (orange), IgG at myogenic differentiation (Diff) stage (blue), and α-H3K9Ac antibody at myogenic differentiation stage (red) (n = 3 each group). ***p < 0.001. (F) ChIP-qPCR analysis of H3K27Ac on the promoter regions of Fermt2. ChIP with IgG at proliferation (Pro) stage (green), α-H3K27Ac antibody at proliferation stage (orange), IgG at myogenic differentiation (Diff) stage (blue), and α-H3K27Ac antibody at myogenic differentiation stage (red) (n = 3 each group). ***p < 0.001.